Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The high rate of new drug approvals in 2018 (Nat. Rev. Drug Discov.18, 328; 2019) continued in 2019. To investigate the mechanistic novelty of new drugs approved in the United States, the European Union and Japan last year, we annotated their mechanism of action (MoA) biomolecular targets (as defined in Nat. Rev. Drug Discov.16, 19–34; 2017), based on package inserts and primary literature. Here, we highlight the novel MoA targets for these drugs; that is, the targets that had not previously been modulated by an approved drug (Table 1).
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery19, 300 (2020)
doi: https://doi.org/10.1038/d41573-020-00052-w
Acknowledgements
This article is part of a series from the NIH Common Fund Illuminating the Druggable Genome (IDG) programme. The goal of IDG is to catalyse research on understudied proteins from druggable gene families by providing reagents, phenotypes and a mineable database; focusing on GPCRs, kinases and ion channels. For more information, see https://druggablegenome.net/